<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585855</url>
  </required_header>
  <id_info>
    <org_study_id>P3-0323</org_study_id>
    <nct_id>NCT03585855</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)</brief_title>
  <official_title>Autologous Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Slovenian Research Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transplant rejection is one of the biggest limitations in renal transplant procedures, where
      the kidney can undergo an acute, late acute, or chronic transplant rejection. With the
      advancement in transplantation protocols, acute survival of renal transplants has improved,
      but long-term survival is still unsatisfactory, as most of the renal transplants develop
      chronic graft rejection. Unfortunately, there is little the investigators know when it comes
      to improving long-term survival of renal transplants. Mesenchymal stem cells (MSC) have been
      shown to have immunosuppressive and repairing properties. The purpose of this study is to
      find out whether MSC in combination with standard therapy of antibody mediated rejection
      (ABMR) are more effective in preventing organ deterioration and maintaining kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be assigned to receive the full immunosuppressive therapy indicated to
      treat chronic ABMR (including plasmapheresis (PF) 7x, intravenous immune globulins 100 mg/kg
      7x, corticosteroid) and MSC infusions (2x106cells/kg bw after PF) (Group 1) and be compared
      to historic controls according to &quot;propensity score matching&quot; (treated with immunosuppressive
      therapy alone (Group 2)). Patients will undergo MSC infusions at the start of the study after
      each PF. One year post- infusions, patients will be evaluated and undergo kidney biopsies.
      Blood collection will occur at regular intervals, serum creatinine and the estimated
      creatinine clearance will be monthly recorded. The transplanted kidney function and
      morphology (US Doppler) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety reasons
  </why_stopped>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>comparison with historic control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MSC transplantation as assessed by adverse events according to CTCAE Version 5Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events according to CTCAE Version 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 months</time_frame>
    <description>eGFR at up to 12 months post MSC transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>Graft survival rate at 12 months post MSC transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Interventional</condition>
  <arm_group>
    <arm_group_label>Historic control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>historic cohort of patients with ABMR treated with standard of care therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with ABMR treated with MSC transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSC transplantation</intervention_name>
    <description>MSC transplantation: patients with ABMR treated with MSC transplantation</description>
    <arm_group_label>MSC transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of a renal allograft, male and female patients age &gt;18

          -  The eGF&gt;20 ml/min/1.73 m2,

          -  Renal biopsy Criteria: chronic active ABMR.

          -  Written informed consent, compliant with local regulations.

        Exclusion Criteria:

          -  Recipients of multiple organs.

          -  Pregnant women.

          -  Malignant disease in last 5 years

          -  Active autoimmune disease

          -  Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis

          -  Evidence of congestive cardiac failure and/or acute coronary syndrome in past 6
             months.

          -  Evidence of liver disease

          -  Inadequate compliance to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Željka Večerić-Haler, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>assist.prof.Željka Večerić-Haler, MDPhD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Veceric-Haler Zeljka</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>12 months</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

